NCT00749411 - Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2008

Primary Completion Date

February 12, 2009

Study Completion Date

February 12, 2009

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Placebo

matching placebo

DRUG

GSK233705/GW642444

The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.

Trial Locations (12)

GSK Investigational Site, Erie

GSK Investigational Site, Spartanburg

GSK Investigational Site, Greenville

GSK Investigational Site, Mobile

GSK Investigational Site, Johnson City

GSK Investigational Site, St Louis

GSK Investigational Site, San Antonio

GSK Investigational Site, Wheat Ridge

GSK Investigational Site, Medford

GSK Investigational Site, Spokane

GSK Investigational Site, Biddeford

GSK Investigational Site, Summit